Cervantes Villarreal E, García Zamarripa H R, Herrera Prado E, Barrón Vallejo J
Hospital Regional, Dr. Alejandro Castanedo Kimball, PEMEX, Salamanca, Gto.
Ginecol Obstet Mex. 1995 Aug;63:328-30.
The therapeutical effectiveness of gestrinone in endometriosis treatment, as well as its long term side effects, were evaluated. Prospective, clinical trial. At "Dr. Alejandro Castanedo Kimball" Hospital (PEMEX). Salamanca, Guanajuato. México. Thirty women with laparoscopically confirmed endometriosis, were studied. Subjects received 2.5 mg. of gestrinone two times per week for 6 months. Laparoscopy was performed before treatment, and clinical response was determined by second laparoscopy after 6 months. The pregnancy rate, frequency of side effects and recurrence of symptoms were determined. Median total endometriosis scores and symptoms decreased significantly after treatment. Four pregnancies were observed after treatment. The principal side effects were: ponderal increase, changes in the voice and hirsutism. However, the side effects disappeared after one year of clinical survey. The results indicate that gestrinone is effective in the treatment of pelvic endometriosis. In despite of a clear benefic effect on stage of the disease and symptoms; the use of gestrinone should weigh the risk-benefit (cost versus metabolic side effects) of treatment.
评估了孕三烯酮治疗子宫内膜异位症的疗效及其长期副作用。前瞻性临床试验。在墨西哥瓜纳华托州萨拉曼卡市的“亚历杭德罗·卡斯塔内多·金博尔博士”医院进行。研究了30名经腹腔镜确诊为子宫内膜异位症的女性。受试者每周两次服用2.5毫克孕三烯酮，持续6个月。治疗前进行腹腔镜检查，并在6个月后通过第二次腹腔镜检查确定临床反应。确定妊娠率、副作用发生率和症状复发情况。治疗后，子宫内膜异位症总评分中位数和症状显著降低。治疗后观察到4例妊娠。主要副作用为：体重增加、声音改变和多毛症。然而，经过一年的临床观察，副作用消失。结果表明，孕三烯酮对盆腔子宫内膜异位症有效。尽管对疾病分期和症状有明显的有益作用，但使用孕三烯酮应权衡治疗的风险效益（成本与代谢副作用）。
